TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07524946: Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

Sponsor: Bausch Health Americas, Inc. · Phase: PHASE4 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 100 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,135,200

Rescue Site Savings

+$743,040

Unlock Full NCT07524946 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07524946 Rescue Dossier →